Figure 4.

Antitumor efficacy of the combination of CD55-TRAIL with luteolin in vivo. (A) The tumor volume was measured every 5 days using the formula V (mm³)=1/2xlength xwidth². Data are presented as the mean ± standard deviation, n=5. ***P<0.001. (B) The apoptosis of tumor sections was assayed using TUNEL staining. The cellular necrotic areas in the tumors were detected using HE staining. The TRAIL expression in tumor tissues was detected by immunohistochemical staining. (C) The toxicity to liver, kidney and spleen tissues was detected by HE staining. Magnification, ×200. HE, hematoxylin and eosin; CD55, complement decay-accelerating factor; TRAIL, tumor necrosis factor ligand superfamily member 10; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.